Next Article in Journal
Identification and Validation of Reference Genes for Seashore Paspalum Response to Abiotic Stresses
Next Article in Special Issue
Adipokines in Liver Cirrhosis
Previous Article in Journal
The Arabidopsis GPR1 Gene Negatively Affects Pollen Germination, Pollen Tube Growth, and Gametophyte Senescence
Previous Article in Special Issue
Subcutaneous and Visceral Adipose Tissue Secretions from Extremely Obese Men and Women both Acutely Suppress Muscle Insulin Signaling

Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction

Department of Pediatrics, Louisiana State University Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71103, USA
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2017, 18(6), 1321;
Received: 7 April 2017 / Revised: 12 June 2017 / Accepted: 13 June 2017 / Published: 21 June 2017
(This article belongs to the Special Issue Adipokines)
Adiponectin is the most abundant peptide secreted by adipocytes, whose reduction plays a central role in obesity-related diseases, including insulin resistance/type 2 diabetes and cardiovascular disease. In addition to adipocytes, other cell types, such as skeletal and cardiac myocytes and endothelial cells, can also produce this adipocytokine. Adiponectin effects are mediated by adiponectin receptors, which occur as two isoforms (AdipoR1 and AdipoR2). Adiponectin has direct actions in liver, skeletal muscle, and the vasculature.Adiponectin exists in the circulation as varying molecular weight forms, produced by multimerization. Several endoplasmic reticulum ER-associated proteins, including ER oxidoreductase 1-α (Ero1-α), ER resident protein 44 (ERp44), disulfide-bond A oxidoreductase-like protein (DsbA-L), and glucose-regulated protein 94 (GPR94), have recently been found to be involved in the assembly and secretion of higher-order adiponectin complexes. Recent data indicate that the high-molecular weight (HMW) complexes have the predominant action in metabolic tissues. Studies have shown that adiponectin administration in humans and rodents has insulin-sensitizing, anti-atherogenic, and anti-inflammatory effects, and, in certain settings, also decreases body weight. Therefore, adiponectin replacement therapy in humans may suggest potential versatile therapeutic targets in the treatment of obesity, insulin resistance/type 2 diabetes, and atherosclerosis. The current knowledge on regulation and function of adiponectin in obesity, insulin resistance, and cardiovascular disease is summarized in this review. View Full-Text
Keywords: adiponectin; obesity; type 2 diabetes; endothelial dysfunction adiponectin; obesity; type 2 diabetes; endothelial dysfunction
Show Figures

Figure 1

MDPI and ACS Style

Achari, A.E.; Jain, S.K. Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction. Int. J. Mol. Sci. 2017, 18, 1321.

AMA Style

Achari AE, Jain SK. Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction. International Journal of Molecular Sciences. 2017; 18(6):1321.

Chicago/Turabian Style

Achari, Arunkumar E., and Sushil K. Jain 2017. "Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction" International Journal of Molecular Sciences 18, no. 6: 1321.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop